Updated: 04/2024

Request for Prior Authorization for Tepezza (teprotumumab-trbw Website Form - www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158

All requests for Tepezza (teprotumumab-trbw) require a Prior Authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Tepezza (teprotumumab-trbw) Prior Authorization Criteria:

For all requests for Tepezza (teprotumumab-trbw) all of the following criteria must be met:

- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- Is age-appropriate according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature
- Must be prescribed by or in consultation with a specialist in ophthalmology or endocrinology

Coverage may be provided with a diagnosis of Thyroid Eye Disease (TED) and the following criteria is met:

- Must be euthyroid or have thyroxine and free triiodothyronine levels less than 50% above or below normal
- **Initial Duration of Approval:** Eight infusions
- Reauthorization criteria
 - o Requests outside 8 total infusions require documentation of peer-reviewed compendia supporting the member's healthcare outcome will be improved by dosing beyond the FDA approved treatment duration.
- **Reauthorization Duration of approval:** up to 8 infusions (dependent on peer-reviewed compendia support provided)

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peerreviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

Drugs are authorized in generic form unless the branded product is on the preferred drug list or the prescriber has indicated in writing that the branded product is medically necessary. If only the branded product is on the preferred drug list, the generic form will be considered non-preferred and shall not require the prescriber to indicate in writing that the branded product is medically necessary.

Updated: 04/2024

TEPEZZA (TEPROTUMUMAB-TRBW) PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Health Options Pharmacy Services. FAX: (855) 476-4158 If needed, you may call to speak to a Pharmacy Services Representative.

PHONE: (844) 325-6251 Monday through Friday 8:00am to 7:00pm

	PROVIDER I	NFORMA	TION		
Requesting Provider:			NPI:		
Provider Specialty:			Office Contact:		
Office Address:			Office Phone:		
			Office Fax:		
	MEMBER I	NFORMAT	ION		
Member Name: DOI					
Member ID: Member				pounds or	kg
	REQUESTED DR	UG INFOI	RMATION	1	
Medication: Streng			h:		
Frequency: Durati					
			To Date Medication Initiated:		
	chronic or long-term condi	tion for wh	ich the med	lication may be necessary for the lif	e of
the patient? Yes No					
	Billing I	nformatio	1		
This medication will be billed:	at a pharmacy OR				
medically (if medically please provide a JCODE:					
Place of Service: Hospital Provider's office Member's home Other					
	Place of Serv	ice Inform	ation		
Name:			NPI:		
Address:			Phone:		
MEDICAL HISTORY (Complete for ALL requests)					
Diagnosis: ICD10 Code:					
Is the member euthyroid or have the	yroxine and free triiodothy	ronine leve	ls less than	50% above or below normal	
limits? Yes No					
	CURRENT or PR				
Medication Name	Strength/ Frequency	Dates of	Therapy	Status (Discontinued & Why/Cu	ırrent)
SUPPORTING INFORMATION or CLINICAL RATIONALE					
Prescribing Providence	er Signature			Date	